Study of Atezolizumab Combination Carboplatin + Paclitaxel + Bevacizumab in EGRF Mutation or ALK Translocation NSCLC
Clinical trial NCT03991403 · UNKNOWN
Trial details
- NCT number
- NCT03991403
- Sponsor
- Samsung Medical Center
- Status
- UNKNOWN
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2019-08-27
- Primary completion
- 2023-03-11
- Enrollment
- 228
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.